<DOC>
	<DOCNO>NCT01121042</DOCNO>
	<brief_summary>The aim study evaluate overall effectiveness Ondansetron adjunctive `` add-on '' medication treatment Schizophrenia . This study double blind , placebo-controlled , randomise , 12 week trial .</brief_summary>
	<brief_title>Double Blind , Placebo-Controlled , Randomised Investigation Ondansetron Schizophrenia</brief_title>
	<detailed_description>Ondansetron medication currently approve Australian Therapeutic Goods Administration treatment drug-induced vomit nausea . Beyond traditional use several case report small clinical trial advocate use Ondansetron treatment adult Schizophrenia . Overall study lend support use Ondansetron conjunction mainstream antipsychotic medication improve positive symptom associate Schizophrenia also 'hard treat ' negative cognitive symptom . Furthermore , Ondansetron may also potential benefit reduce adverse motor effect ( e.g . tremor , uncontrolled muscle movement ) associate use many antipsychotic medication . 60 participant age 18-65 inclusive DSM-IV diagnosis Schizophrenia , Schizoaffective , Schizophreniform disorder recruit . This study propose conduct randomize , control treatment trial investigate efficacy ondansetron adjunctive treatment reduce negative positive symptom plus improve cognitive symptom . There initial screening session determine participant suitability , baseline session study medication ( Ondansetron Placebo ) dispense , follow three monitor visit . The efficacy Ondansetron evaluate follow instrument : - Positive Negative Symptom Scale ( PANSS ) - Montgomery-Ã…sberg Depression Rating Scale ( MADRS ) - C-Reactive protein ( marker systematic brain specific inflammation ) Safety assess adverse event report use Adverse symptom Checklist ( ASC ) , blood analysis , urinalysis , 12-lead Electrocardiogram ( ECG ) physical examination . Adverse motor symptom also assess Abnormal Involuntary Movement Scale Simpson-Angus Scale . In addition safety monitoring committee consist research medical staff external project regularly review adverse event .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Aged 1865 year age 2 . Have current DSMIVTR diagnosis schizophrenia , schizoaffective schizophreniform disorder ( diagnosis confirm use MINI Neuropsychiatric Interview ) 3 . Have treat stable standard dose ( determined PORT Treatment Recommendations schizophrenia [ 33 ] ) atypical antipsychotic agent ( include amisulpride owe 5HT3 action ) primary antipsychotic treatment minimum eight week entry trial 4 . Are experience positive symptom evidence score &gt; 15 Positive Syndrome Subscale PANSS , and/or negative psychotic symptom evidence score &gt; 15 Negative Syndrome Subscale PANSS /or significant cognitive dysfunction , evidence least 15 cognitive subscale . The cognition subscale use study , include item G10 , G11 , G12 , P2 , N5 , N7 PANSS generate previous study . 5 . Have level understanding sufficient provide inform consent communicate investigator , study coordinator , site personnel . 1 . Have unstable medical condition , neurological disorder unstable seizure disorder . Any clinical significant electrocardiogram ( ECG ) abnormality screening , include sinus bradycardia ( ersting heart rate &lt; 50 beat per minute ) , atrial fibrillation , 2nd 3rd degree AV block ( AVB ) , prolong ATc ( QTcF &gt; 450ms male &gt; 470ms female ) history congenital long AT syndrome , risk Torsades de Pointes family history sudden death . 2 . Currently pregnant breastfeed 3 . Have current DSMIVTR diagnosis substance abuse dependence disorder , another Axis I disorder 4 . Regularly use another 5HT3 antagonist metoclopramide , cocaine , tropisetron , granisetron , palonosetron</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>